ASCO 2024 Myelofibrosis Roundtable

CME

Myelofibrosis Expert Roundtable: State-of-the-Art Clinical Advances and Therapeutic Strategies From JAK Inhibition Into the Future

Physicians: Maximum of 1.50 AMA PRA Category 1 Credits

Released: June 18, 2024

Expiration: June 17, 2025

Prithviraj Bose
Prithviraj Bose, MD
Lucia Masarova
Lucia Masarova, MD
Raajit K. Rampal
Raajit K. Rampal, MD, PhD

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

  • 72-yr-old woman newly diagnosed with MF

  • Symptoms: fatigue, significant night sweating, weight loss, and abdominal pain

  • Labs: Hgb 9.7 g/dL, WBC count 22 x 109/L with 1% blasts, platelets 40 x 109/L

Presurvey 1: In your current practice, which of the following would you choose as the best therapeutic strategy for this patient?

2.

  • 68-yr-old woman with symptomatic post-PV MF with splenomegaly; began ruxolitinib 10 mg BID, unable to tolerate higher dose

  • Now has progressive disease, TSS 14, maximum spleen length 22 cm (11 cm BCM); WBC count 35.5 x 109/L; hemoglobin 7.1 g/dL; platelets: 110 x 109/L; 2% blasts

Presurvey 2: In your current practice, which of the following would you choose as the best therapeutic strategy for this patient?

3.

Presurvey 3: Regarding the outcomes from the phase III MANIFEST-2 trial of pelabresib + ruxolitinib vs placebo + ruxolitinib for patients with JAK inhibitor–naive, higher-risk MF, all of the following are true EXCEPT which one?